The active ingredient in MOTRIN is ibuprofen, which is a member of the propionic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Ibuprofen is a racemic mixture of [+]S- and [-]R-enantiomers. It is a white to off-white crystalline powder, with a melting point of 74° to 77°C. It is practically insoluble in water (<0.1 mg/mL), but readily soluble in organic solvents such as ethanol and acetone. Ibuprofen has a pKa of 4.43±0.03 and an n-octanol/water partition coefficient of 11.7 at pH 7.4. The chemical name for ibuprofen is (±)-2-(p-isobutylphenyl) propionic acid. The molecular weight of ibuprofen is 206.28. Its molecular formula is C 13 H 18 O 2 and it has the following structural formula:


MOTRIN Suspension is a sucrose-sweetened, orange-colored, berry-flavored liquid suspension containing 100 mg of ibuprofen in 5 mL (20 mg/mL). Inactive ingredients include citric acid, glycerin, polysorbate 80, pregelatinized starch, purified water, sodium benzoate, sucrose, xanthan gum, D&C Yellow #10 and FD&C Red #40, and artificial flavors.

MOTRIN Oral Drops (intended for pediatric use only) is a sucrose-sweetened, pink-colored, berry-flavored liquid suspension containing 40 mg of ibuprofen per mL. Inactive ingredients include citric acid, glycerin, polysorbate 80, pregelatinized starch, purified water, sodium benzoate, sorbitol, sucrose, xanthan gum, FD&C Red #40, and artificial flavors.

MOTRIN Chewable Tablets are aspartame-sweetened, citrus-tasting, orange-colored tablets, that contain 50 mg or 100 mg of ibuprofen per tablet. Inactive ingredients include aspartame, citric acid, hydroxyethyl cellulose, hydroxypropyl methylcellulose, magnesium stearate, mannitol, microcrystalline cellulose, povidone, sodium lauryl sulfate, sodium starch glycolate, FD&C Yellow #6, and artificial flavors.

MOTRIN Caplets are unsweetened, white-colored, unflavored, film-coated, capsule-shaped tablets, containing 100 mg of ibuprofen per tablet. Inactive ingredients include carnauba wax, colloidal silicone dioxide, cornstarch, hydroxypropyl methylcellulose, microcrystalline cellulose, polydextrose, polyethylene glycol, pregelatinized starch, propylene glycol, sodium starch glycolate, titanium dioxide, triacetin, D&C Yellow #10, and FD&C Yellow #6.

Pharmacodynamics Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that possesses anti-inflammatory, analgesic and antipyretic activity. Its mode of action, like that of other NSAIDs, is not completely understood, but may be related to prostaglandin synthetase inhibition. After absorption of the racemic ibuprofen, the [-]R-enantiomer undergoes interconversion to the [+]S-form. The biological activities of ibuprofen are associated with the [+]S-enantiomer.

In clinical studies in adult patients with rheumatoid arthritis and osteoarthritis, ibuprofen has been shown to be comparable to aspirin in controlling pain and inflammation, though causing fewer of the mild gastrointestinal side effects (see ADVERSE REACTIONS ). MOTRIN may be well tolerated in some patients who have had gastrointestinal side effects with aspirin, but these patients, when treated with MOTRIN, should be carefully followed for signs and symptoms of gastrointestinal ulceration and bleeding. Although it is not definitely known whether ibuprofen causes less peptic ulceration than aspirin, in one study involving 885 adult patients with rheumatoid arthritis treated for up to one year (438 patients on ibuprofen and 447 patients on aspirin), there were no reports of gastric ulceration with ibuprofen whereas frank ulceration was reported in 13 patients in the aspirin group (statistically significant p<.001).

Gastroscopic studies at varying doses of ibuprofen showed an increased tendency toward endoscopic lesions at higher doses. However, at clinically comparable doses (2,400 mg of ibuprofen vs. 3,600 mg of aspirin), endoscopic lesions were approximately half that seen with aspirin. Studies using 51 Cr-tagged red cells indicate that fecal blood loss associated with ibuprofen in doses up to 2400 mg daily did not exceed the range of normal, and was significantly less than that seen in aspirin-treated patients. The clinical significance of these findings is unknown.

As noted in the section, ibuprofen is a racemic mixture of [-]R-and [+]S-isomers. In vivo and in vitro studies indicate that the [+]S-isomer is responsible for clinial activity. The [-]R-form, while thought to be pharmacologically inactive, is slowly and incompletely (60%) interconverted into the active [+]S species in adults. The degree of interconversion in children is unknown, but is thought to be similar. The [-]R-isomer serves as a circulating reservoir to maintain levels of active drug. Ibuprofen is well absorbed orally, with less than 1% being excreted in the urine unchanged. It has a biphasic elimination time curve with a plasma half-life of approximately 2 hours. Studies in febrile children have established the dose-proportionality of 5 and 10 mg/kg doses of ibuprofen. Studies in adults have established the dose-proportionality of ibuprofen as a single oral dose from 50 to 600 mg for total drug and up to 1200 mg for free drug.

Absorption-- In vivo studies indicate that ibuprofen is well absorbed orally from the suspension, drops, caplet and chewable tablet formulations, with peak plasma levels usually occurring within 1 to 2 hours. The pharmacokinetic differences between the products in adults (see Table 1) are due to differences in the rate of absorption of ibuprofen from the various dosage forms. The observed differences in the table between adults and children, in terms of AUC and C max , are due to both differences in dose per body weight and age-or fever-related change in volume of distribution (Vd/F). All of the formulations are equally bioavailable in terms of peak plasma levels (C max ) and extent of absorption (AUC), however, the time-to-peak (T max ) is different between the products. Clinically, this has been shown to have no effect on either onset or peak fever reduction in children.

Table 1
Pharmacokinetic Parameters of Ibuprofen Formulations
[Mean Values (% coefficient of variation)]
200mg (=2.8 mg/kg) in Adults 10 mg/kg in Febrile Children
Suspension Drops Caplet Chewable Tablet Suspension Chewable Tablet
Number of Patients
24 24 25 24 18 18
AUCinf (µg·h/mL)
64 74 60 66 155 176
(27%) (19%) (19%) (22%) (24%) (25%)
Cmax (µg/mL)
19 24 20 15 55 43
(22%) (21%) (18%) (24%) (23%) (39%)
Tmax (h)
0.79 1.0 1.04 2.0 0.97 1.43
(69%) (60%) (50%) (56%) (57%) (69%)
Cl/F (mL/h/kg)
45.6 43.4 45.0 42.8 68.6 60.9
(22%) (18%) (19%) (18%) (22%) (27%)
Legend: AUCinf = Area-under-the-curve to infinity
Tmax = Time-to-peak plasma concentration
Cmax = Peak plasma concentration
Cl/F = Clearance divided by fraction at drug absorbed

Antacid A bioavailability study in adults has shown that there was no interference with the absorption of ibuprofen when given in conjunction with an antacid containing both aluminum hydroxide and magnesium hydroxide.

Food Effects-- Absorption is most rapid when MOTRIN is given under fasting conditions. Administration of MOTRIN Suspension, MOTRIN Oral Drops, MOTRIN Chewable Tablets and MOTRIN Caplets with food affects the rate but not the extent of absorption. When taken with food, T max is delayed by approximately 30 to 60 minutes, and peak levels are reduced by approximately 30 to 50%.

Distribution Ibuprofen, like most other drugs of its class, is highly protein bound (>99% bound at 20 µg/mL). Protein binding is saturable and at concentrations >20 µg/mL binding is non-linear. Based on oral dosing data there is an age-or fever-related change in volume of distribution for ibuprofen. Febrile children <11 years old have a volume of approximately 0.2 L/kg while adults have a volume of approximately 0.12 L/kg. The clinical significance of these findings is unknown.

Metabolism Following oral administration, the majority of the dose was recovered in the urine within 24 hours as the hydroxy-(25%) and carboxypropyl-(37%) phenylpropionic acid metabolites. The percentages of free and conjugated ibuprofen found in the urine were approximately 1% and 14%, respectively. The remainder of the drug was found in the stool as both metabolites and unabsorbed drug.

Elimination-- Ibuprofen is rapidly metabolized and eliminated in the urine. The excretion of ibuprofen is virtually complete 24 hours after the last dose. It has a biphasic plasma elimination time curve with a half-life of approximately 2.0 hours. There is no difference in the observed terminal elimination rate or half-life between children and adults, however, there is an age-or fever-related change in total clearance. This suggests that the observed change in clearance is due to changes in the volume of distribution of ibuprofen (see Table 1 for Cl/F values).

Clinical Studies-- Controlled clinical trials comparing doses of 5 and 10 mg/kg ibuprofen suspension and 10-15 mg/kg of acetaminophen elixir have been conducted in children 6 months to 12 years of age with fever primarily do to viral illnesses. In these studies there were no differences between treatment in fever reduction for the first hour and maximum fever reduction occurred between 2 and 4 hours. Response after 1 hour was dependent on both the level of temperature elevation as well as the treatment. In children with baseline temperatures at or below 102.5°F both ibuprofen doses and acetaminophen were equally effective in their maximum effect. In children with temperatures above 102.5°F, the ibuprofen 10 mg/kg dose was more effective. By 6 hours, children treated with ibuprofen 5mg/kg tended to have recurrence in fever, whereas children treated with ibuprofen 10 mg/kg still had significant fever reduction at 8 hours. In control groups treated with 10 mg/kg acetaminophen, fever reduction resembled that seen in children treated with 5 mg/kg of ibuprofen, with the exception that temperature elevation tended to return 1-2 hours earlier.

A comparison of MOTRIN Chewable Tablets and MOTRIN Suspension in febrile children showed similar antipyretic effects of the two formulations, lasting between 6 and 8 hours. No clinical studies of fever reduction in children have been performed with MOTRIN Caplets or MOTRIN Oral Drops.

Controlled single-dose clinical analgesia trials comparing doses of 5 and 10 mg/kg ibuprofen suspension with acetaminophen suspension 12.5 mg/kg and placebo, have been conducted in children 5 to 12 years of age, with sore throat pain due to an infectious agent, or ear pain due to acute otitis media. Onset of pain relief provided by ibuprofen was similar to that of acetaminophen, occurring within the first hour, usually around the half-hour mark. All active treatments showed significant pain relief verus placebo, and the 10 mg/kg dose of ibuprofen had a duration of analgesic effect of 6 to 8 hours. Ibuprofen 10 mg/kg provided more overall pain relief than the 5 mg/kg dose.

Controlled studies have demonstrated that ibuprofen is a more effective analgesic than propoxyphene for the relief of episiotomy pain, pain following dental extraction procedures, and for the relief of the symptoms of primary dysmenorrhea.

In patients with primary dysmenorrhea, ibuprofen has been shown to reduce elevated levels of prostaglandin activity in the menstrual fluid and to reduce resting and active intrauterine pressure, as well as the frequency of uterine contractions. The probable mechanism of action is to inhibit prostaglandin synthesis rather than simply to provide analgesia.

In clinical studies in adult patients with rheumatoid arthritis, ibuprofen has been shown to be comparable to indomethacin in controlling the signs and symptoms of disease activity, with a lower incidence of milder gastrointestinal and CNS side effects than indomethacin.

MOTRIN may be used in combination with gold salts and/or corticosteroids.

In Children

MOTRIN is indicated:

In Adults

MOTRIN is indicated:

Since there have been no controlled trials to demonstrate whether there is any beneficial effect or harmful interaction with the use of ibuprofen in conjuction with aspirin, the combination cannot be recommended (see PRECAUTIONS -- Drug Interactions ).


MOTRIN should not be used in patients with previously demonstrated hypersensitivity to ibuprofen, or in individuals with a history of allergic manifestations to aspirin or other NSAIDs. Severe anaphylactic-like reactions to ibuprofen have been reported in such patients, some with fatal outcome.

Risk of GI Ulceration, Bleeding and Perforation with NSAID Therapy. Serious gastrointestinal toxicity such as bleeding, ulceration, and perforation, can occur at any time, with or without warning symptoms, in patients treated chronically with NSAID therapy. Although minor upper gastrointestinal problems, such as dyspepsia, are common, usually developing early in therapy, physicians should remain alert for ulceration and bleeding in patients treated chronically with NSAIDs even in the absence of previous GI tract symptoms. In patients observed in clinical trials of several months to two years duration, symptomatic upper GI ulcers, gross bleeding or perforation appear to occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year. Physicians should inform patients about the signs and/or symptoms of serious GI toxicity and what steps to take if they occur.

Studies to date have not identified any subset of patients not at risk of developing peptic ulceration and bleeding. Except for a prior history of serious GI events and other risk factors known to be associated with peptic ulcer disease, such as alcoholism, smoking, etc., no risk factors (e.g., age, sex) have been associated with increased risk. Elderly or debilitated patients seem to tolerate ulceration or bleeding less well than other individuals and most spontaneous reports of fatal GI events are in this population. Studies to date are inconclusive concerning the relative risk of various NSAIDs in causing such reactions. High doses of any NSAID probably carry a greater risk of these reactions, although controlled clinical trials showing this do not exist in most cases. In considering the use of relatively large doses (within the recommended dosage range), sufficient benefit should be anticipated to offset the potential increased risk of GI toxicity.

Anaphylactoid Reactions:   Anaphylactoid reactions may occur even in patients without prior exposure to ibuprofen. Extreme caution should be exercised when giving MOTRIN to patients with bronchospastic reactivity (e.g., asthma), nasal polyps, or those with a history of angiodema. Emergency help should be sought in case such anaphylactoid reaction occurs.

Advanced Renal Disease: In cases with advanced kidney disease, treatment with MOTRIN should not be initiated; if MOTRIN is used in such cases, close monitoring of the patient's kidney functions is advisable (see PRECAUTIONS --Renal Effects).


Renal Effects:   Caution should be used when initiating treatment with MOTRIN in patients with considerable dehydration. It is advisable to rehydrate patients first and then start therapy with MOTRIN. Caution is also recommended in patients with pre-existing kidney disease (see --Advanced Renal Disease).

As with other NSAIDs, long-term administration of ibuprofen to animals has resulted in renal papillary necrosis and other abnormal renal pathology. In humans, there have been reports of acute interstitial nephritis with hematuria, proteinuria, and occasionally nephrotic syndrome.

A second form of renal toxicity has been seen in patients with prerenal conditions leading to a reduction in renal blood flow or blood volume, where the renal prostaglandins have a supportive role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and the elderly. Discontinuation of NSAID therapy is typically followed by recovery to the pre-treatment state.

Those patients at high risk, who chronically take ibuprofen, should have renal function monitored if they have signs or symptoms which may be consistent with mild azotemia, such as malaise, fatigue, loss of appetite, etc. Occasional patients may develop some elevation of serum creatinine and BUN levels without signs or symptoms.

Since ibuprofen is eliminated primarily by the kidneys, patients with significantly impaired renal function should be closely monitored and a reduction in dosage should be anticipated to avoid drug accumulation. Prospective studies on the safety of ibuprofen in patients with chronic renal failure have not been conducted.

Fluid Retention: Fluid retention and edema have been reported in association with ibuprofen, therefore, the drug should be used with caution in patients with a history of cardiac decompensation or hypertension.

Hematologic Effects: MOTRIN can inhibit platelet aggregation but, unlike aspirin, its effect on platelet function is reversible, quantitatively less, and of shorter duration. Because this prolonged bleeding effect may be exaggerated in patients with underlying hemostatic defects, MOTRIN should be used with caution in persons with intrinsic coagulation defects and those on anticoagulant therapy.

Hepatic Effects: As with other nonsteroidal anti-inflammatory drugs, borderline elevations of one or more liver laboratory tests may occur in up to 15% of patients. These abnormalities may progress, may remain essentially unchanged, or may be transient with continued therapy. The ALT (SGPT) test is probably the most sensitive indicator of liver dysfunction. Meaningful (3 times the upper limit of normal) elevations of ALT and AST (SGOT) occurred in controlled clinical trials in less than 1% of patients. A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of more severe hepatic reactions while on therapy with MOTRIN. Severe hepatic reactions, including jaundice and cases of fatal hepatitis, have been reported with ibuprofen as with other nonsteroidal anti-inflammatory drugs. Although such reactions are rare, if abnormal liver tests persist or worsen, if clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), treatment with MOTRIN should be discontinued.

Aseptic Meningitis: Aseptic meningitis, with fever and coma, has been observed on rare occasions in patients on ibuprofen therapy. Although it is probably more likely to occur in patients with systemic lupus erythematosus and related connective tissue diseases, it has been reported in patients who do not have an underlying chronic disease. If signs or symptoms of meningitis develop in a patient receiving MOTRIN, the possibility of its being related to ibuprofen should be considered.

Other Precautions-- The pharmacological activity of MOTRIN may induce fever reduction and inflammation, thus diminishing their utility as diagnostic signs in detecting underlying conditions.

In order to avoid exacerbation of manifestations of adrenal insufficiency, patients who have been on prolonged corticosteroid therapy should have their therapy tapered slowly rather than discontinued abruptly when ibuprofen is added to the treatment program.

Blurred and/or diminished vision, scotomata, and/or changes in color vision have been reported. If a patient develops such complaints while receiving MOTRIN Chewable Tablets, the drug should be discontinued and the patient should have an ophthalmologic examination which includes central visual fields and color vision testing.

Phenylketonurics: MOTRIN Chewable Tablets 50 mg contain phenylalanine 3 mg per tablet, and the 100 mg tablets contain phenylalanine 6 mg per tablet.

Diabetics: MOTRIN Suspension and MOTRIN Oral Drops contain 0.3 g sucrose and 1.6 calories per mL, or 1.5 g sucrose and 8 calories per teaspoon, which should be taken into consideration when treating diabetic patients with this product.

Information for Patients-- MOTRIN, like other drugs of its class, is not free of side effects. The side effects of these drugs can cause discomfort and, rarely, there are more serious side effects, such as gastrointestinal bleeding, which may result in hospitalization and even fatal outcomes.

NSAIDs are often essential agents in the management of arthritis, pain and fever, but they also may be commonly employed for conditions which are less serious.

Physicians may wish to discuss with their patients the potential risks (see , PRECAUTIONS , and ADVERSE REACTIONS ) and likely benefits of NSAID treatment, particularly when the drugs are used for less serious conditions where treatment without NSAIDs may represent an acceptable alternative to both the patient and physician.

Patients on MOTRIN should report to their physicians signs or symptoms of gastrointestinal ulceration or bleeding, blurred vision or other eye symptoms, skin rash, weight gain, or edema.

Because serious GI tract ulceration and bleeding can occur without warning symptoms, physicians should follow chronically treated patients for the signs and symptoms of ulceration and bleeding and should inform them of the importance of this follow-up (see ).

Patients should also be instructed to seek medical emergency help in case of an occurrence of an anaphylactoid reaction (see ).


Hemoglobin Levels:   In cross-study comparisons, in adults, with doses ranging from 1200 mg to 3200 mg daily for several weeks, a slight dose-response decrease in hemoglobin/hematocrit was noted. This has been observed with other nonsteroidal anit-inflammatory drugs; the mechanism is unknown. However, even with daily doses of 3200 mg, the total decrease in hemoglobin usually does not exceed 1 g/dL; if there are no signs of bleeding, it is probably not clinically important.

In two postmarketing clinical studies with ibuprofen, the incidence of a decreased hemoglobin level was greater than previously reported. Decrease in hemoglobin of 1 g/dL or more was observed in 17.1% of 193 patients on 1600 mg ibuprofen daily (osteoarthritis), and 22.8% of 189 patients taking 2400mg of ibuprofen daily (rheumatoid arthritis). Positive stool occult blood tests and elevated serum creatinine levels were also observed in these studies.


Coumarin-type anticoagulants:   Several short-term controlled studies failed to show that iburprofen significantly affected prothrombin times or a variety of other clotting factors administered to individuals on coumarin-type anticoagulants. Because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering MOTRIN to patients on anticoagulants.

Aspirin:   Animal studies show that aspirin given with NSAIDs, including ibuprofen, yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug. Single-dose bioavailability studies in normal volunteers have failed to show an effect of aspirin on ibuprofen blood levels. Correlative clinical studies have not been done.

Methotrexate:   Ibuprofen, as well as other NSAIDs, has been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that ibuprofen could enhance the toxicity of methotrexate. Caution should be used, therefore, if MOTRIN is administered concomitantly with methotrexate.

H-2 Antagonists:   In studies with human volunteers, coadministration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.

ACE-inhibitors:   Reports suggest that NSAIDs, including ibuprofen, may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking MOTRIN concomitantly with ACE-inhibitors.

Furosemide:   Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with MOTRIN, the patient should be observed closely for signs of renal failure (see PRECAUTIONS , Renal Effects), as well as to assure diuretic efficacy.

Lithium:   Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers. The mean minimum lithium concentration increased 15% and the renal clearance of lithium was decreased by 19% during this period of concomitant drug administration. This effect has been attributed to inhibition of renal prostaglandin synthesis by ibuprofen. Thus, when MOTRIN and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity. (Read circulars for lithium preparation before use of such concurrent therapy.)

Teratogenic Effects--Pregnancy Category B: Reproductive studies conducted in rats and rabbits at doses somewhat less than the maximal clinical dose did not demonstrate evidence of developmental abnormalities. However, animal reproduction studies are not always predictive of human response. As there are no adequate and well-controlled studies in pregnant women, this drug should be used during pregnancy only if clearly needed. Because of the known effects of nonsteroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during late pregnancy should be avoided. Administration of MOTRIN is not recommended during pregnancy.

Labor and Delivery: As with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia and delayed parturition occurred in rats. Administration of MOTRIN is not recommended during labor and delivery.

Nursing Mothers: In limited studies, an assay capable of detecting 1 µg/mL did not demonstrate ibuprofen in the milk of lactating mothers. Because of the limited nature of these studies, however, and the possible adverse effects of prostaglandin inhibiting drugs on neonates, MOTRIN is not recommended for use in nursing mothers.

Pediatric Use: Safety and efficacy of MOTRIN in children below the age of 6 months has not been established (see -Clinical Studies). There is no evidence of age-dependent kinetics in patients 2 to 11 years old (see - ). Dosing of MOTRIN in children 6 months or older should be guided by their body weight (see DOSAGE AND ADMINISTRATION ).


The most frequent type of adverse reaction occurring with ibuprofen is gastrointestinal. In controlled clinical trials, the percentage of adult patients reporting one or more gastrointestinal complaints ranged from 4% to 16%.

In controlled studies in adults, when ibuprofen was compared to aspirin and indomethacin in equally effective doses, the overall incidence of gastrointestinal complaints was about half that seen in either the aspirin- or indomethacin-treated patients.

Adverse reactions observed during controlled clinical trials in adults at an incidence greater than 1% are listed in the chart. Those reactions listed under the heading "Incidence Greater than 1% (but less than 3%) Probable Causal Relationship," encompass observations in approximately 3,000 patients. More than 500 of these patients were treated for periods of at least 54 weeks.

Still other reactions, occurring less frequently than 1 in 100, were reported in controlled clinical trials and from marketing experience. These reactions have been divided into two categories: "Incidence less than 1%--Probable Causal Relationships," lists reactions with Ibuprofen therapy for which the probability of a causal relationship exists; this category was completed over time with postmarketing serious adverse reactions. "Incidence less than 1% --Causal Relationship Unknown," lists reactions with ibuprofen therapy for which a causal relationship has not been established, but are presented as alerting information for physicians.


Probable Causal Relationship

Incidence between 3 and 9%=ADR marked with*

Incidence between 1 and <3%=unmarked ADR

Cardiovascular system: Edema, fluid retention (generally responds promptly to drug discontinuation) (See PRECAUTIONS ).

Digestive system: Nausea*, epigastric pain*, heartburn*, diarrhea, abdominal distress, nausea and vomiting, indigestion, constipation, abdominal cramps or pain, fullness of Gl tract (bloating and flatulence).

Nervous system: Dizziness*, headache, nervousness.

Skin and appendages:   Rash* (including maculopapular type), pruritus

Specal senses:   Tinnitus.


Probable Causal Relationship: The following adverse reactions were reported in clincial trials at an incidence of less than 1%, or were reported from postmarketing or foreign experience. The probability exists between the drug and these adverse reactions.

Body as a whole:   Anaphylaxis and anaphylactoid reactions (see ).

Cardiovascular system: Cerebrovascular accident, hypotension, congestive heart failure in patients with marginal cardiac function, elevated blood pressure, palpitations.

Digestive system: Gastric or duodenal ulcer with bleeding and/or perforation, gastrointestinal hemorrhage, pancreatitis, melena, gastritis, duodenitis, esophagitis, hematemesis, hepatorenal syndrome, liver necrosis, liver failure, hepatitis, jaundice, abnormal liver tests.

Hematologic system: Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia (sometimes Coombs positive), thrombocytopenia with or without purpura, eosinophilia, decrease in hemoglobin and hematocrit (see PRECAUTIONS ), pancytopenia.

Nervous system: Depression, insomia, confusion, emotional liability, somnolence, convulsions, aseptic meningitis with fever and coma (see PRECAUTIONS ).

Respiratory:   Bronchospasm, dyspnea, apnea.

Skin and appendages:   Vesiculobullous eruptions, urticaria, erythema multiforme, Stevens-Johnson syndrome, alopecia, exfoliative dermatitis, Lyell' syndrome (toxic epidermal necrolysis), photosensitivity reactions.

Special senses:   Hearing loss, amblyopia (blurred and/or diminished vision, scotomata and/or changes in color vision) (see PRECAUTIONS --Other Precautions).

Urogenital system: Acute renal failure in patients with pre-existing significantly impaired renal function (see PRECAUTIONS ), renal papillary necrosis, tubular necrosis, glomerulitis, decreased creatinine clearance, polyuria, azotemia, cystitis, hematuria.

Miscellaneous:   Dry eyes and mouth, gingival ulcer, rhinitis.


Causal Relationship Unknown:   The following adverse reactions occurred at an incidence of less than 1% in clinical trials, or were suggested by marketing experience under circumstances where a causal relationship could not be definitely established. They are listed as alerting information for the physician.

Allergic:   Serum sickness, lupus erythematosus syndrome, Henoch-Sch[omacr ]nlein vasculitis, angioedema.

Cardivascular system: Arrhythmias (sinus tachycardia, sinus bradycardia).

Hematologic system: Bleeding episodes (e.g., epistaxis, menorrhagia).

Metabolic/endocrine:   Gynecomastia, hypoglycemic reaction, acidosis.

Nervous system: Paresthesias, hallucinations, dream abnormalities, pseudo-tumor cerebri.

Special senses:   Conjunctivitis, diplopia, optic neuritis, cataracts.


The toxicity of ibuprofen overdose is dependent upon the amount of drug ingested and the time elapsed since ingestion, though individual response may vary, which makes it necessary to evaluate each case individually. Although uncommon, serious toxicity and death have been reported in the medical literature with ibuprofen overdosage. The most frequently reported symptoms of ibuprofen overdose include abdominal pain, nausea, vomiting, lethargy and drowsiness. Other central nervous system symptoms include headache, tinnitus, CNS depression and seizures. Metabolic acidosis, coma, acute renal failure and apnea (primarily in very young children) may rarely occur. Cardiovascular toxicity, including hypotension, bradycardia, tachycardia and atrial fibrillation, also have been reported.

The treatment of acute ibuprofen overdose is primarily supportive. Management hypotension acidosis and gastrointestinal bleeding may be necessary. In cases of acute overdose, the stomach should be emptied through ipecac-induced emesis or lavage. Emesis is most effective if initiated within 30 mintues of ingestion. Orally administered activated charcoal may help in reducing the absorption and reabsorption of ibuprofen.

In children, the estimated amount of ibuprofen ingested per body weight may be helpful to predict the potential for development of toxicity although each case must be evaluated. Ingestion of less than 100 mg/kg is unlikely to produce toxicity. Children ingesting 100 to 200 mg/kg may be managed with induced emesis and a minimal observation time of four hours. Children ingesting 200 to 400 mg/kg of ibuprofen should have immediate gastric emptying and at least four hours observation in a health care facility. Children ingesting greater than 400 mg/kg require immediate medical referral, careful observation and appropriate supportive therapy. Ipecac-induced emesis is not recommended in overdoses greater than 400 mg/kg because of the risk for convulsions and the potential for aspiration of gastric contents.

In adult patients the history of the dose reportedly ingested does not appear to be predictive of toxicity. The need for referral and follow-up must be judged by the circumstances at the time of the overdose ingestion. Symptomatic adults should be admitted to a health care facility for observation.



Fever reduction: For reduction of fever in children, 6 months to 12 years of age, the dosage should be adjusted on the basis of the initial temperature level (see ). The recommended dose is 5 mg/kg if the baseline temperature is less than 102.5°F, or 10 mg/kg if the baseline temperature is 102.5°F or greater. The duration of fever reduction is generally 6 to 8 hours. The recommended maximum daily dose is 40 mg/kg.

Analgesia:   For relief of mild to moderate pain in children, 6 months to 12 years of age, the recommended dosage is 10 mg/kg, every 6 to 8 hours. The recommended maximum daily dose is 40 mg/kg. Doses should be given so as not to disturb the child's sleep pattern. Taking fluids after chewing MOTRIN Chewable Tablets may help to promote absorption of the drug (see -- , and "Individualization of Dosage" in this section).

Juvenile Arthritis: The recommended dose is 30 to 40 mg/kg/day divided into three to four doses (see Individualization of Dosage). Patients with milder disease may be adequately treated with 20 mg/kg/day.


Analgesia:   400 mg every 4 to 6 hours as necessary for the relief of mild to moderate pain in adults. In controlled analgesic clincial trials, doses of MOTRIN greater than 400 mg were no more effective than the 400 mg dose.

Primary Dysmenorrhea: For the treatment of primary dysmenorrhea, beginning with the earliest onset of such pain, MOTRIN should be given in a dose of 400 mg every 4 hours, as necessary, for the relief of pain.

Rheumatoid arthritis and osteoarthritis, including flare-ups of chronic disease: Suggested dosage: 1200-3200 mg daily (300 mg q.i.d or 400 mg, 600 mg or 800 mg t.i.d. or q.i.d). Individual patients may show a better response to 3200 mg daily, as compared with 2400 mg, although in well-controlled clinical trials patients on 3200 mg did not show a better mean response in terms of efficacy. Therefore, when treating patients with 3200 mg/day, the physician should observe sufficient increased clincial benefits to offset potential increased risk.

Individualization of Dosage The dose of MOTRIN should be tailored to each patient, and may be lowered or raised from the suggested doses depending on the severity of symptoms either at time of initiating drug therapy or as the patient responds or fails to respond.

One fever study showed that, after the initial dose of MOTRIN, subsequent doses may be lowered and still provide adequate fever control.

In a situation when low fever would require the MOTRIN 5 mg/kg dose in a child with pain, the dose that will effectively treat the predominant symptom should be chosen.

In chronic conditions, a therapeutic response to MOTRIN therapy is sometimes seen in a few days to a week, but most often is observed by two weeks. After a satisfactory response has been achieved, the patient' dose should be reviewed and adjusted as required.

In patients with juvenile arthritis, doses above 50 mg/kg/day are not recommended because they have not been studied and doses exceeding the upper recommended dose of 40 mg/kg/day may increase the risk of causing serious adverse events. The therapeutic response may require from a few days to several weeks to be achieved. Once a clincial effect is obtained, the dosage should be lowered to the smallest dose of MOTRIN needed to maintain adequate control of symptoms.

In general, patients with rheumatoid arthritis seem to require higher doses than do patients with osteoarthritis. The smallest dose of MOTRIN that yields acceptable control should be employed.


MOTRIN® (ibuprofen) Suspension 100 mg/5 mL

Orange-colored, berry-flavored suspension

-Bottles of 120 mL--NDC 0045-0448-04

-Bottles of 480 mL--NDC 0045-0448-16

Shake well before using. Store at controlled room temperature [15° to 30°C (59° to 86°F)]

MOTRIN® (ibuprofen) Oral Drops, 40mg/mL

(intended for pediatric use only)

Pink-colored, berry flavored suspension

-Bottles of 15 ml--NDC 0045-0446-15

Shake well before using. Store at controlled room temperature [15° to 30°C (59° to 86°F)].

MOTRIN® (ibuprofen) Chewable Tablets, 50 mg

Round, orange-colored, citrus-tasting, scored tablet, debossed "MOTRIN 50"

-Bottles of 100 Chewable Tablets--NDC 0045-0361-10

Store at controlled room temperature [15° to 30°C (59° to 86°F)]

MOTRIN® (ibuprofen) Chewable Tablets, 100 mg

Round, orange-colored, citrus-tasting, scored tablet, debossed "MOTRIN 100"

-Bottles of 100 Chewable Tablets--NDC 0045-0431-10

Store at controlled room temperature [15° to 30°C (59° to 86°F)]

MOTRIN® (ibuprofen) Caplets, 100 mg

White-colored, scored capsule-shaped tablet, imprinted "M 100"

-Bottles of 100 Caplets--NDC 0045-0445-10

Store at controlled room temperature [15° to 30°C (59° to 86°F)]

Caution:   Federal Law prohibits dispensing without prescription.






NOTE: These photos can be used only for identification by shape, color, and imprint. They do not depict actual or relative size.

The product samples shown here have been supplied by the manufacturer and reproduced in full color by PDR as a quick-reference identification aid. While every effort has been made to assure accurate reproduction, please remember that any visual identification should be considered preliminary. In cases of poisoning or suspected overdosage, the drug' identity should be verified by chemical analysis.